Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 620 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Ivosidenib with Chemotherapy New Option for Some People with AML May 13, 2022 Potential for Larger Gene Panels to Increase the Number of Molecularly... April 22, 2025 Beating cancer by improving the public’s health: the road ahead in... December 4, 2020 Load more HOT NEWS 6 things you need to know about cervical screening Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... A Penny for Your Thoughts Trial Establishes Preferred Treatment for Some People with Esophageal Cancer
